Best Life Sciences Companies in Seongnam-si, South Korea
The 105 best Life Sciences companies in Seongnam-si, South Korea in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Genexine.
Our analysis of 50 Life Sciences companies
$4.0b in tracked funding; 40% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Seongnam-si
| # | Company | Disclosed funding | Last round | Stage | Founder | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Genexine Developer of immunotherapeutics for treating orphan diseases, cancers & autoimmune disorders 40Product top 14%Patents top 25%Innovation top 32%Funding top 38% All 11 signals ▾Producttop 14% Patentstop 25% Innovationtop 32% Fundingtop 38% Talenttop 38% Moattop 41% Growthtop 45% Globalbottom 45% Marketbottom 37% Fin. healthbottom 34% Techbottom 23% Product: 10 distinct product lines · Company stage: Public Patents: 357 patents matched (strict assignee match) · 113 filings since 2022 vs 151 in 2017-21 rank vs industry peers · Fliar Intelligence Index 40/100 | $233M | 99 mo ago | Public | Young Sung Founder & Chairman | 2002 | NginxGoogle Font APIUnpkg+6 | 357 patents Therapeutic protein engineering and antibody-based cancer immunotherapies. | — |
| 2 | D&D Pharmatech Developer of GLP-1-based therapeutics for metabolic disease treatment 42Patents top 19%Funding top 23%Innovation top 28%Moat top 32% All 9 signals ▾Patentstop 19% Fundingtop 23% Innovationtop 28% Moattop 32% Talentbottom 49% Globalbottom 42% Marketbottom 39% Fin. healthbottom 39% Techbottom 31% Patents: 92 patents matched (strict assignee match) · 62 filings since 2022 vs 27 in 2017-21 Funding: Raised $205M across 4 rounds · 4 rounds over 8 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 42/100 | $205M | 12 mo ago | Public | Seulki Lee Founder | 2014 | PHPGSAPApache HTTP Server+9 | 92 patents Peptide bioconjugates with biotin/fatty acid for oral drug delivery | — |
| 3 | CHA Biotech Developer of stem cell therapeutics 40Funding top 23%News top 31%Partners top 32%Moat top 38% All 11 signals ▾Fundingtop 23% Newstop 31% Partnerstop 32% Moattop 38% Growthtop 42% Patentstop 43% Talentbottom 49% Innovationbottom 46% Techbottom 43% Marketbottom 36% Globalbottom 35% Funding: Raised $67.8M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) News: 5 BI events in 12 mo (of 12 tracked, 5 types) · +25% YoY rank vs industry peers · Fliar Intelligence Index 40/100 | $68M | 5 mo ago | Public | Sang Oh CEO | 2000 | WordPressMySQLPHP+11 | 74 patents Umbilical cord stem cell therapies and NK cell immunotherapies for reproductive and cancer treatments | — |
| 4 | ABL Bio Bi-specific antibodies and Antibody-drug Conjugate immunotherapies for oncology and neurodegenerative diseases | $65M | 96 mo ago | Public | Sang Hoon Lee Ceo/Founder | 2016 | OpenSSLBootstrapApache HTTP Server+5 | 273 patents Bispecific therapeutic antibodies targeting tumor antigens and immune co‑stimulatory receptors | — |
| 5 | ImmuneOncia Developer of monoclonal and specific antibody for cancer treatment 11Funding top 37%Moat top 39%Market bottom 32%Global bottom 32% All 5 signals ▾Fundingtop 37% Moattop 39% Marketbottom 32% Globalbottom 32% Techbottom 23% Funding: Raised $60.5M across 2 rounds · 2 rounds over 7 yrs (0.3/yr) Moat: Editorial + unicorn rating 7/10 · 10 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 11/100 | $60M | 53 mo ago | Public | — | 2016 | PHPGSAPApache HTTP Server+7 | — | — |
| 6 | Organoid Sciences Developer of regenerative medicines for multiple diseases | $39M | 53 mo ago | Public | Jongman Yoo CEO | 2019 | WordPressMySQLPHP+22 | — | — |
| 7 | Aprogen 🦄 Biotechnology company producing Biosimilars | $31M | 85 mo ago | Late Stage | — | 2000 | DreamWeaverJavaUNIX+10 | 63 patents Therapeutic antibody formulations targeting TNF‑α and CD43 for inflammatory and cancer treatments | — |
| 8 | 1ST Bio Developer of therapies for treating neurodegenerative and immuno-oncology diseases 53Funding top 28%Talent top 28%Market bottom 46%Global bottom 37% All 4 signals ▾Fundingtop 28% Talenttop 28% Marketbottom 46% Globalbottom 37% Funding: Raised $22.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Talent: Analyst team rating 4/5 rank vs industry peers · Fliar Intelligence Index 53/100 | $22M | 4 mo ago | Series D | — | 2016 | — | — | — |
| 9 | MediMabBio Developer of immunotherapeutics for treating cancer 29Moat top 32%Funding top 35%Talent top 38%Patents top 40% All 8 signals ▾Moattop 32% Fundingtop 35% Talenttop 38% Patentstop 40% Innovationtop 42% Globalbottom 31% Marketbottom 30% Techbottom 26% Moat: Editorial + unicorn rating 5/10 · IP moat: 28 patents Funding: Raised $17.8M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 29/100 | $18M | 7 mo ago | Series B | Hongseok Jo Co-Founder | 2017 | WordPressMySQLPHP+12 | 28 patents Immune checkpoint antibodies (TIGIT, GITR) and cytokine‑fusion therapeutics for cancer immunotherapy | — |
| 10 | NOVOREX Developer of drugs for the treatment of cancer and central nervous diseases 32Funding top 33%AI top 45%Moat top 45%Patents top 50% All 8 signals ▾Fundingtop 33% AItop 45% Moattop 45% Patentstop 50% Talentbottom 45% Innovationbottom 38% Globalbottom 36% Marketbottom 34% Funding: Raised $15.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) AI: Product described with: artificial intelligence rank vs industry peers · Fliar Intelligence Index 32/100 | $15M | 2 mo ago | Series B | Woosung Son CEO | 2020 | — | 4 patents Small‑molecule inhibitors of LRRK2 kinase and YEATS epigenetic reader domains | — |
| 11 | Bertis Developer of AI-based diagnostic platform for cancer and cardiac diseases | $13M | 60 mo ago | Series B | Inhoi Koo Co-Founder | 2014 | GnuboardMySQLPHP+15 | 81 patents Cancer biomarker detection using advanced mass spectrometry and liquid chromatography methods | — |
| 12 | Amyloid Solution Provider of therapeutics solution for treating Alzheimer’s disease | $13M | 86 mo ago | Series A | Jintae Chang CEO | 2017 | — | 46 patents Glycine transporter modulators and amyloid‑beta detection compounds for neurodegenerative disease therapy | — |
| 13 | QuadMedicine Provider of patch for vaccine delivery | $12M | 49 mo ago | Public | Seung-Ki Baek CEO | 2016 | jQueryGoogle WorkspaceGoDaddy+1 | 38 patents Transdermal microneedle patches for combined drug delivery, thermal therapy, and fluid sensing | — |
| 14 | Speclipse Provider of molecular spectroscopy systems for early-stage skin cancer detection | $11M | 58 mo ago | Acquired | — | 2015 | GnuboardMySQLPHP+11 | 124 patents AI-driven skin cancer imaging diagnostics and point‑of‑care analyte measurement devices | — |
| 15 | Bridge Biotherapeutics Developer of small molecule based therapeutics for the treatment of various diseases | $10M | 107 mo ago | Acquired | James Jungkue Lee Founder & CEO | 2015 | PHPNginxCloudflare+10 | 36 patents Small‑molecule autotaxin inhibitors and PROTACs for targeted protein degradation therapies. | — |
| 16 | Novelty Nobility Developer of therapeutics for eye and cancer diseases | $8M | 76 mo ago | Series A | Sang Park Founder & CEO | 2018 | — | 55 patents Therapeutic antibodies and ADCs targeting c‑Kit, CDCP1, VEGF, HIF‑1α for cancer and mast‑cell diseases | — |
| 17 | EXOSYSTEMS Developer of a wearable medical device used for rehabilitation | $4M | 55 mo ago | Series A | Hooman Lee Founder & Co-CEO | 2016 | — | 30 patents Patents concentrated in health & consumer products | — |
| 18 | Genome & Company Developer of microbiome-based immuno-oncology drugs | $3M | 73 mo ago | Public | Jisoo Pae Co-Founder & CEO | 2015 | — | 252 patents Patents concentrated in computing, sensing & instrumentation | — |
| 19 | Posture 360 Provider of body aligning device | $700K | — | Deadpooled | William Choi Founder & CEO | 2016 | — | 2 patents Protective wearable gear for spinal support integrated into backpacks and footwear. | — |
Top 12 Life Sciences companies in Seongnam-si
#1
Public · Seongnam-si, Gyeonggi-do · founded 2000$67.8Mraised▾
Developer of stem cell therapeutics. The company's pluripotent stem cells therapeutics include hESC-RPE (embryonic-derived RPE cells) and SCNT-RPE (somatic cell replication RPE cells) used to treat Stargardt disease and atrophic age-related macular degeneration. The company's adult stem cells therapeutic includes PLX-PAD (placental mesenchymal-like cells) for Intermittent Lameness and Severe limb ischemia, eCASs (enhanced umbilical cord stem cells) for acute stroke and degenerative disc disease, fetal–NPC (Nerve Progenitor Cell) for Parkinson's disease, and adipose-derived mesenchymal stem cells for degenerative lumbar vertebra. The company also aims to develop immune cell therapy to treat Relapsed glioblastoma.
- Jan 2026Post IPO$67.8M
#2
Series B · Seongnam-si, Gyeonggi-do · founded 2020 · 20 employees$15Mraised▾
Developer of drugs for the treatment of cancer and central nervous diseases. The company develops GPCR-targeted small-molecule drugs using artificial intelligence to treat neurological disorders, cognitive function, and cancer.
- Apr 2026Series B$15M
#3
Public · Seongnam-si, Gyeonggi-do · founded 2014 · 16 employees$204.7Mraised▾
Developer of GLP-1-based therapeutics for metabolic disease treatment. It focuses on building on a robust foundation of proprietary peptide research and strategic collaborations. D&D Pharmatech is advancing a diverse pipeline of therapeutics for metabolic, fibrotic, and neurodegenerative diseases. The global biotech company’s umbrella structure comprises three U.S. subsidiaries, including Neuraly Inc, its clinical research arm responsible for conducting clinical trials for the company’s pipeline, including its dual agonist (GLP-1/glucagon) for metabolic dysfunction-associated steatohepatitis (MASH).
- Jun 2025Post IPO$10.8M
- Oct 2021Series C$51M
- Feb 2020Grant (prize money)—
- Aug 2019Series B$137.1M
#4
Series D · Seongnam-si, Gyeonggi-do · founded 2016 · 34 employees$22Mraised▾
1ST Bio is developing therapies for treating neurodegenerative and immuno-oncological diseases. The lead candidate of the company, 1ST 102 is a tyrosine kinase enzyme inhibitor. It's in the preclinical phase which is used for treating Parkinson's Disease. Other candidates like 1ST-101 and 1ST-103 are in the discovery stage.
- Jan 2026Series D$22M
#5
Series B · Seongnam-si, Gyeonggi-do · founded 2017 · 19 employees$17.8Mraised▾
MediMabBio is a developer of immunotherapeutics for treating cancer. The company develops immuno-oncology drugs using its drug discovery platform with a combination of systems biology and immunological solutions to target solid tumors. The products pipeline includes immune checkpoint antibody (MMB-101) in lead optimization stage and immuno cytokine agents (MMB-201) in hit optimization stage.
- Oct 2025Series B$17.8M
#6
Public · Seongnam-si, Gyeonggi-do · founded 2002$233Mraised▾
Developer of immunotherapeutics for treating orphan diseases, cancers & autoimmune disorders. The company has developed drug candidates for Growth Hormone Deficiencies, Cervical Cancers, and Anemias. Its technology is based on Fc fusion proteins and DNA Vaccines.
- Mar 2018Post IPO$233M
#7
Public · Seongnam-si, Gyeonggi-do · founded 2016 · 21 employees$60.5Mraised▾
Developer of monoclonal and specific antibody for cancer treatment. The company's lead antibody IMC-001 is currently in phase 1 of the clinical trial. The company has a pipeline of immune checkpoint antibodies against undisclosed targets for both hematological malignancies and solid tumors.
- Jan 2022Series B$20.5M
- Feb 2019Series A$40M
#8
Public · Seongnam-si, Gyeonggi-do · founded 2019 · 70 employees$39Mraised▾
Organoid Sciences is a developer of regenerative medicines for multiple diseases. It uses cannabinoid-based technology for the development of a regenerative medicine pipeline.
- Jan 2022Series B$32.5M
- Mar 2020Series A$6.4M
#9
Public · Seongnam-si, Gyeonggi-do · founded 2016 · 93 employees$65Mraised▾
ABL Bio is a Korean, clinical-stage biopharma developing immunotherapies for oncology and neurodegenerative diseases. Their first lead candidate is ABL001 a bispecific antibody targeting DII4 & VEGF and is indicated for solid tumors. The second bispecific antibody is ABL301, a BBB penetrating Bispecific antibody for targeting Alpha-Synuclein, and indicated for Parkinson's Disease and other synucleopathies. The company is developing 4 ADCs for various cancer indications (MM, AML, CLL, TNBC).
- Jun 2018Series C$65M
- 2016Seed—
#10
Public · Seongnam-si, Gyeonggi-do · founded 2016 · 49 employees$11.7Mraised▾
Provider of patch for vaccine delivery
- May 2022Series C$11.7M
- Nov 2021Seed—
- Jan 2020Seed—
- Series B—
#11
Aprogen 🦄Late Stage · Seongnam-si, Gyeonggi-do · founded 2000 · 66 employees$30.7Mraised▾
Aprogen is a Korean Biotech that develops its own biologics and also biosimilars. It is developing biosimilar products for various biologics including infliximab, trastuzumab, adalimumab, and bevacizumab. In terms of novel biologics, it is developing AP185, AP216, and other new candidates targeted for vascular disease and oncology market. Currently, Aprogen can manufacture over 80 kg of APIs of biopharmaceuticals annually and it has undertaken construction of the second factory with annual manufacturing capacity over 2,000 kg of API and a fill-finish facility, which is expected to be completed by the end of 2017. The first lead candidate, AP185, is a fusion protein of the functional C-terminal domain of angiopoietin 1 (Ang1) and short coiled-coil domain of cartilage oligomeric matrix protein (COMP). AP185 indicated for damaged blood vessels caused by myocardial infarction, diabetic foot ulcer, and erectile dysfunction. The second lead candidate, AP216, is a fusion protein of angiopoietin binding domain of TIE2, Ig2 domain of VEGFR, and Fc domain of immunoglobulin G1. AP216 blocks angiogenic action in various cancers, such as ovarian and lung cancers, by effective suppression of
- May 2019PE$16.7M
- Jul 2012PE$14M
#12
Series B · Seongnam-si, Gyeonggi-do · founded 2014 · 46 employees$13.5Mraised▾
Developer of AI-based diagnostic platform for cancer and cardiac diseases. The company's lead product MASTOCHECK is a proteomics-based blood test to detect breast cancer. Another product is a cardiovascular disease marker which is a non-invasive blood test that detects the biomarkers present in the blood.
- Jun 2021Series B$13.5M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.